MULPLETA

This brand name is authorized in Japan, United States

Active ingredients

The drug MULPLETA contains one active pharmaceutical ingredient (API):

1 Lusutrombopag
UNII 6LL5JFU42F - LUSUTROMBOPAG

Lusutrombopag is an orally active TPO receptor agonist. Lusutrombopag acts on the haematopoietic stem cells and on the transmembrane domain of human TPO receptors expressed in megakaryocytes, to stimulate the megakaryocyte to proliferate and differentiate via the similar signal transduction pathway for up-regulating production used by endogenous TPO, thus leading to thrombocytopoiesis.

Read about Lusutrombopag

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: JP 医薬品医療機器総合機構 Identifier(s): 3399010F1022
Country: US FDA, National Drug Code Identifier(s): 59630-551

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.